Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
specificA primary cutaneous diffuse large B-cell lymphoma, leg type that is resistant to treatment.
15
Centers
16
Active Trials
—
Cancer Funding
Top Centers for Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type(15)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL High-Volume Research Center | 74.3 |
| 2 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 51.8 |
| 3 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 51.8 |
| 4 | NCI Comprehensive Active Research Program | 51.8 |
| 5 | NCI Comprehensive Active Research Program | 51.8 |
| 6 | NCI Comprehensive Active Research Program | 51.8 |
| 7 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 51.8 |
| 8 | Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program | 51.8 |
| 9 | Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive Active Research Program | 51.8 |
| 10 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 51.8 |
| 11 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 51.8 |
| 12 | Dartmouth Cancer CenterLebanon, NH NCI Comprehensive Active Research Program | 51.8 |
| 13 | University of Illinois Cancer CenterChicago, IL Active Research Program | 51.8 |
| 14 | Cancer Center at IllinoisUrbana, IL Active Research Program | 51.8 |
| 15 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ Active Research Program | 51.8 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →